Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Famprofazone is a nonsteroidal anti-inflammatory drug (NSAID) of the pyrazolone series with analgesic, anti-inflammatory, and antipyretic effects. It is available over-the-counter in some countries such as Taiwan and is found in multi-ingredient medications like Gewodin and Gewolen. Famprofazone acts primarily by inhibiting cyclooxygenase (COX), thereby reducing prostaglandin synthesis responsible for pain, inflammation, and fever. A notable pharmacological feature of famprofazone is its metabolism to methamphetamine and amphetamine; approximately 15–20% of an oral dose can be converted to methamphetamine. This metabolic pathway has led to positive drug tests for amphetamines in users. Due to safety concerns related to this metabolism, its use has been discontinued or restricted in many countries[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on famprofazone.